Enliven Therapeutics, Inc. · NASDAQ:ELVN

Collins Helen Louise sold 5,000 Enliven Therapeutics, Inc. shares (Form 4)

Traded Apr 17, 2026 · Filed Apr 21, 2026

On Apr 17, 2026, Collins Helen Louise (CHIEF MEDICAL OFFICER) sold 5,000 Enliven Therapeutics, Inc. shares at an average US$47.67 for US$238K under a trading plan, leaving 25,000 shares. Filed Apr 21, 2026 (Form 4).

Sold
5,000 shares
Price
US$47.67 average (US$45.81 to US$48.06)
Value
US$238K
Holding after
25,000 shares
Trading plan
Yes (Made under a plan set in advance)
Role
CHIEF MEDICAL OFFICER

The filing in full

DateSecurityTransactionSharesPriceHolding afterOwnership
Apr 17, 2026Common StockOption exercise5,000US$2.4830,000Direct
Apr 17, 2026Common StockSale140US$45.8129,860Direct
Apr 17, 2026Common StockSale2,419US$47.3927,441Direct
Apr 17, 2026Common StockSale2,441US$48.0625,000Direct

Source

View original at SEC

Related